Publicacións en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (29)

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2021

  1. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  2. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  3. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

2015

  1. Whole-genome fingerprint of the DNA methylome during human B cell differentiation

    Nature Genetics, Vol. 47, Núm. 7, pp. 746-756

2013

  1. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

    Haematologica, Vol. 98, Núm. 9, pp. 1414-1420

  2. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

    Leukemia, Vol. 27, Núm. 4, pp. 925-931

2012

  1. A DNA methylation fingerprint of 1628 human samples

    Genome Research, Vol. 22, Núm. 2, pp. 407-419

  2. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours

    Scientific Reports, Vol. 2

  3. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

  4. Quantification of miRNA-mRNA interactions

    PLoS ONE, Vol. 7, Núm. 2

  5. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

    PLoS ONE, Vol. 7, Núm. 2

2011

  1. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, Núm. 30, pp. 12461-12466

  2. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

  3. Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells

    Molecular Cancer Research, Vol. 9, Núm. 8, pp. 1139-1151

2009

  1. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms

    PLoS ONE, Vol. 4, Núm. 9

  2. Epigenetic signatures associated with different levels of differentiation potential in human stem cells

    PLoS ONE, Vol. 4, Núm. 11